Tumour Necrosis Factor (TNF)

Tumour Necrosis Factor (TNF) designates a pro-inflammatory cytokine produced primarily by immune cells that regulates immune activation, inflammation, apoptosis, and host defence, playing central roles in autoimmune diseases, chronic inflammation, and immune-mediated tissue damage. TNF signalling occurs through TNF receptors, activating pathways that drive cytokine production, cell survival, or cell death depending on context.

The biopharmaceutical industry has developed TNF inhibitors as major therapeutic class transforming treatment of autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, psoriasis, and ankylosing spondylitis. Approved therapies include monoclonal antibodies and receptor fusion proteins that neutralise TNF activity, reducing inflammation and improving symptoms. Clinical use requires monitoring for infections, as TNF suppression increases susceptibility to tuberculosis and opportunistic pathogens. Development and regulatory considerations include immunogenicity, long-term safety monitoring, and comparative effectiveness across indications. Biosimilar competition has expanded access while maintaining clinical performance. As immunology advances and new inflammatory pathways are targeted, TNF remains a foundational example of cytokine-targeted therapy demonstrating how pathway-specific intervention can deliver major clinical benefit across multiple autoimmune conditions.